# Allogeneic Stem Cell Transplantation in Relapsed/Refractory T-, NK/T-cell Lymphomas

> **NCT02859402** · PHASE2 · RECRUITING · sponsor: **Keimyung University Dongsan Medical Center** · enrollment: 34 (estimated)

## Conditions studied

- T-cell Non-Hodgkin Lymphoma
- Lymphoma, Extranodal NK-T-Cell

## Interventions

- **DRUG:** Busulfan
- **DRUG:** Fludarabine

## Key facts

- **NCT ID:** NCT02859402
- **Lead sponsor:** Keimyung University Dongsan Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2016-12
- **Primary completion:** 2025-12
- **Final completion:** 2027-12
- **Target enrollment:** 34 (ESTIMATED)
- **Last updated:** 2022-08-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02859402

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02859402, "Allogeneic Stem Cell Transplantation in Relapsed/Refractory T-, NK/T-cell Lymphomas". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02859402. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*